Clinical Trials Logo

Recurrent Mycosis Fungoides clinical trials

View clinical trials related to Recurrent Mycosis Fungoides.

Filter by:
  • None
  • Page 1

NCT ID: NCT03075553 Recruiting - Clinical trials for Recurrent Adult T-Cell Leukemia/Lymphoma

Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma

Start date: May 17, 2017
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well nivolumab works in treating patients with peripheral T-cell lymphoma that has come back after a period of improvement or that does not respond to treatment. Monoclonal antibodies, such as nivolumab, may block cancer growth in different ways by targeting certain cells.

NCT ID: NCT03017820 Active, not recruiting - Clinical trials for Recurrent Adult Acute Myeloid Leukemia

VSV-hIFNbeta-NIS in Treating Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia, or T-cell Lymphoma

Start date: April 4, 2017
Phase: Phase 1
Study type: Interventional

This phase I trial studies the best dose and side effects of recombinant vesicular stomatitis virus carrying the human NIS and IFN beta genes (VSV-hIFNbeta-sodium iodide symporter [NIS]) in treating patients with multiple myeloma, acute myeloid leukemia, or T-cell lymphoma that has come back or does not respond to treatment. A virus, called VSV-hIFNbeta-NIS, which has been changed in a certain way, may be able to kill cancer cells without damaging normal cells.

NCT ID: NCT03011814 Recruiting - Clinical trials for Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma

Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma

Start date: February 14, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

This randomized phase I/II trial studies the best dose and side effects of durvalumab and to see how well it works with or without lenalidomide in treating patients with cutaneous or peripheral T cell lymphoma that has come back and does not respond to treatment. Monoclonal antibodies, such as durvalumab, may interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving durvalumab and lenalidomide may work better in treating patients with cutaneous or peripheral T cell lymphoma.

NCT ID: NCT02702310 Recruiting - Clinical trials for Refractory Mycosis Fungoides

Low-Dose Total Skin Electron Therapy in Treating Patients With Refractory or Relapsed Stage IB-IIIA Mycosis Fungoides

Start date: April 2016
Phase: N/A
Study type: Observational

This clinical trial studies low- dose total skin electron therapy in treating patients with stage IB-IIIA mycosis fungoides that has not responded to previous treatment (refractory) or has returned after a period of improvement (relapsed). Radiation therapy uses high energy electrons to kill tumor cells and shrink tumors. Rotisserie technique is a method in which the patient receives total skin electron therapy while standing on a rotating platform. Giving low dose total skin electron therapy using rotisserie technique may kill tumor cells, while having fewer side effects, and may allow therapy to be repeated in future if clinically indicated.